These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17559351)

  • 1. ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.
    Lubomirov R; Csajka C; Telenti A
    Pharmacogenomics; 2007 Jun; 8(6):623-33. PubMed ID: 17559351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of anti-HIV drugs.
    Telenti A; Zanger UM
    Annu Rev Pharmacol Toxicol; 2008; 48():227-56. PubMed ID: 17883329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics in HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nacher I; Rendón A; Soriano V
    AIDS Rev; 2005; 7(2):103-12. PubMed ID: 16092504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.
    Tarr PE; Rotger M; Telenti A
    Pharmacogenomics; 2010 Apr; 11(4):587-94. PubMed ID: 20350140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
    Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
    Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.
    Neary M; Owen A
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1169-1181. PubMed ID: 28994310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
    Arab-Alameddine M; Décosterd LA; Buclin T; Telenti A; Csajka C
    Expert Opin Drug Metab Toxicol; 2011; 7(5):609-22. PubMed ID: 21500966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses.
    Feng J; Sun J; Wang MZ; Zhang Z; Kim ST; Zhu Y; Sun J; Xu J
    Pharmacogenomics; 2010 Oct; 11(10):1403-25. PubMed ID: 21047203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa.
    Pallerla SR; Elion Assiana DO; Linh LTK; Cho FN; Meyer CG; Fagbemi KA; Adegnika AA; Beng VP; Achidi EA; Kahunu GM; Bates M; Grobusch MP; Kremsner PG; Ntoumi F; Velavan TP
    Int J Infect Dis; 2021 Mar; 104():207-213. PubMed ID: 33310105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of HIV therapy.
    Owen A; Pirmohamed M; Khoo SH; Back DJ
    Pharmacogenet Genomics; 2006 Oct; 16(10):693-703. PubMed ID: 17001288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic Markers: A Path toward Individualized HIV Therapy.
    García-Blanco D; Gravier-Hernández R; Rabeiro-Martínez CL; Gil Del Valle L; Pérez-Ávila J
    MEDICC Rev; 2019; 21(2-3):59-68. PubMed ID: 31401638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will pharmacogenomic discoveries improve HIV therapeutics?
    Haas DW
    Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy.
    Telenti A
    Pharmacogenomics; 2009 Apr; 10(4):515-6. PubMed ID: 19374508
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
    Calcagno A; Cusato J; D'Avolio A; Bonora S
    Clin Pharmacokinet; 2017 Apr; 56(4):355-369. PubMed ID: 27641153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV pharmacogenetics in clinical practice: recent achievements and future challenges.
    Tozzi V; Libertone R; Liuzzi G
    Curr HIV Res; 2008 Nov; 6(6):544-54. PubMed ID: 18991620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.